( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible

Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients

Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,836

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766

Recurring mutations found by sequencing an acute myeloid leukemia genome

Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020

Mutation in TET2 in Myeloid Cancers

Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation

Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035

Regulation of the HIF-1α Level Is Essential for Hematopoietic Stem Cells

Takubo, K., Goda, N., Yamada, W., Iriuchishima, H., Ikeda, E., Kubota, Y., Shima, H., Johnson, R. S., Hirao, A., Suematsu, M., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.06.020 · Cited by 891

Biochemical Background in Mitochondria Affects 2HG Production by IDH2 and ADHFE1 in Breast Carcinoma

Špačková, J., Gotvaldová, K., Dvořák, A., Urbančoková, A., Pospíšilová, K., Větvička, D., Leguina‐Ruzzi, A., Tesařová, P., Vı́tek, L., Ježek, P., et al. (2021) · Cancers · doi:10.3390/cancers13071709 · Cited by 13

A metabolic metamorphosis

Krall, A. S., & Christofk, H. R. (2013) · Nature · doi:10.1038/496038a · Cited by 13

Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A

Horton, J. R., Liu, X., Wu, L., Zhang, K., Shanks, J. R., Zhang, X., Rai, G., Mott, B. T., Jansen, D. J., Kales, S. C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00261 · Cited by 13

The Landscape of the Anti-Kinase Activity of the IDH1 Inhibitors

Malarz, K., Mularski, J., Pacholczyk, M., & Musioł, R. (2020) · Cancers · doi:10.3390/cancers12030536 · Cited by 13

Rediscovering Potential Molecular Targets for Glioma Therapy Through the Analysis of the Cell of Origin, Microenvironment and Metabolism

Guo, X., Wang, T., Huang, G., Li, R., Costa, C. D., Li, H., Lv, S., & Li, N. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210504091722 · Cited by 13

Silencing a Metabolic Oncogene

Kim, J., & DeBerardinis, R. J. (2013) · Science · doi:10.1126/science.1238523 · Cited by 13

Isocitrate dehydrogenase mutations are associated with altered IL-1β responses in acute myeloid leukemia

Sunthankar, K. I., Jenkins, M. T., Cote, C. H., Patel, S. B., Welner, R. S., & Ferrell, P. B. (2021) · Leukemia · doi:10.1038/s41375-021-01487-9 · Cited by 12

Rotenone Stereospecifically Increases (S)-2-Hydroxyglutarate in SH-SY5Y Neuronal Cells

Worth, A. J., Gillespie, K. P., Mesaros, C., Guo, L., Basu, S. S., Snyder, N. W., & Blair, I. A. (2015) · Chemical Research in Toxicology · doi:10.1021/tx500535c · Cited by 12

Integrating a prospective pilot trial and patient-derived xenografts to trace metabolic changes associated with acute myeloid leukemia

Carrabba, M. G., Tavel, L., Oliveira, G., Forcina, A., Quilici, G., Nardelli, F., Tresoldi, C., Ambrosi, A., Ciceri, F., Bernardi, M., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0346-2 · Cited by 12

Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy

Li, L., Eid, J. E., Paz, A. C., & Trent, J. C. (2017) · BioDrugs · doi:10.1007/s40259-017-0237-2 · Cited by 12

Identification of different gene expressions between diffuse- and intestinal-type spheroid-forming gastric cancer cells

Lee, J. W., Sung, J. S., Park, Y. S., Chung, S. H., & Kim, Y. H. (2019) · Gastric Cancer · doi:10.1007/s10120-019-00935-x · Cited by 12

Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia

Lachowiez, C., DiNardo, C. D., & Stein, E. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000570 · Cited by 12

Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?

Lue, J. K., Amengual, J. E., & O’Connor, O. A. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0464-y · Cited by 14

Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility

Hou, H., & Tien, H. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1144469 · Cited by 13

The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches

Gruber, E., & Kats, L. M. (2023) · Biochemical Society Transactions · doi:10.1042/bst20230017 · Cited by 11

A Comprehensive Metabolism-Related Gene Signature Predicts the Survival of Patients with Acute Myeloid Leukemia

Zhai, Y., Shen, H., & Wei, H. (2023) · Genes · doi:10.3390/genes15010063 · Cited by 11

Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets

Pichler, A., Amador, C., Fujimoto, A., Takeuchi, K., de Jong, D., Iqbal, J., & Staber, P. B. (2024) · Histopathology · doi:10.1111/his.15376 · Cited by 11

A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives

Gu, J., Wu, Q., Zhang, Q., You, Q., & Wang, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114742 · Cited by 11

Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies

Jiang, X., Wada, R., Poland, B., Kleijn, H. J., Fan, B., Liu, G., Liu, H., Kapsalis, S. M., Yang, H. Q., & Le, K. N. (2021) · Clinical and Translational Science · doi:10.1111/cts.12959 · Cited by 11

Isocitrate dehydrogenase mutations: new opportunities for translational research

Keum, Y., & Choi, B. Y. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.5.021 · Cited by 11

Constitutional abnormalities of IDH1 combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia

Hirabayashi, S., Seki, M., Hasegawa, D., Kato, M., Hyakuna, N., Shuo, T., Kimura, S., Yoshida, K., Kataoka, K., Fujii, Y. R., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26647 · Cited by 11

Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations

Harding, J. J., Oh, D., Macarulla, T. M., Goyal, L., Varkaris, A. S., Palmieri, L., Ikeda, M., Kondo, S., Bai, L., Ueno, M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0174 · Cited by 10

Metabolic regulation of cholestatic liver injury by D-2-hydroxyglutarate with the modulation of hepatic microenvironment and the mammalian target of rapamycin signaling

Tian, X., Wang, Y., Lu, Y., Wu, B. Y., Chen, S., Du, J. C., Cai, W., & Xiao, Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05450-z · Cited by 11

Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse

Tan, Y., Liu, H., & Chen, S. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0423-x · Cited by 10

Induction chemotherapy in acute myeloid leukaemia: origins and emerging directions

Upadhyay, V. A., & Fathi, A. T. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000407 · Cited by 10

3‐(7‐Azaindolyl)‐4‐indolylmaleimides as a novel class of mutant isocitrate dehydrogenase‐1 inhibitors: Design, synthesis, and biological evaluation

Hu, Y., Gao, A., Liao, H., Zhang, M., Xu, G., Gao, L., Xu, L., Zhou, Y., Gao, J., Ye, Q., et al. (2018) · Archiv der Pharmazie · doi:10.1002/ardp.201800039 · Cited by 10

Vascular-endothelial response to IDH1 mutant fibrosarcoma secretome and metabolite: implications on cancer microenvironment.

Mao, M., & Leonardi, D. (2019) · Europe PMC (PubMed Central) · Cited by 9

Assessment of Transporter‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Cheng, Y., Wang, X., Tong, Z., Reyes, J. F., Carayannopoulos, L. N., Zhou, S. Y., & Li, Y. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1979 · Cited by 10

Differentiation therapy for IDH1/2 mutant malignancies

Garrett-Bakelman, F. E., & Melnick, A. M. (2013) · Cell Research · doi:10.1038/cr.2013.73 · Cited by 10

The Molecular Basis of Histone Demethylation

Horton, J. R., Gale, M., Yan, Q., & Cheng, X. (2017) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-59786-7_7 · Cited by 10

Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors

Tecik, M., & Adan, A. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01202-7 · Cited by 9

Inside the Battle Against Acute Myeloid Leukemia: Biology, Breakthroughs, and Hope

Bao, J., Freund, O., Sund, L., & Du, W. (2026) · Cells · doi:10.3390/cells15040338 · Cited by 15

Noncoding rules of survival: epigenetic regulation of normal and malignant hematopoiesis

Wallace, L. M., & Obeng, E. A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1273046 · Cited by 11

Rapid Recognition of Glucose Molecular Fingerprint Using Transmissive Microfluidic Multiplexing Metasensor

Shen, S., & Chen, L. (2024) · IEEE Sensors Journal · doi:10.1109/jsen.2024.3384291 · Cited by 9

Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms

Babakoohi, S., Lapidus, R. G., Faramand, R. G., Sausville, E. A., & Emadi, A. (2016) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000342 · Cited by 9

Interaction between IDH1 WT and calmodulin and its implications for glioblastoma cell growth and migration

Kang, S., Kwon, H. N., Kang, S., & Park, S. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.073 · Cited by 9

Chemical individuality in T cells: A Garrodian view of immunometabolism

McGuire, P. J. (2020) · Immunological Reviews · doi:10.1111/imr.12854 · Cited by 10

Diminished expression of 5hmc in Reed-Sternberg cells in classical Hodgkin lymphoma is a common epigenetic marker

Siref, A. B., McCormack, C. C., Huang, Q., Lim, W., & Alkan, S. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106408 · Cited by 9

Les modèles explicatifs du cancer

Morange, M. (2014) · médecine/sciences · doi:10.1051/medsci/20143006020 · Cited by 9

Cardiometabolic disease and cardio-oncology: Insights from iPSC models and tissue engineering

Kojic, A., Moslehi, J. J., Ky, B., & Wu, J. C. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102261 · Cited by 10

Epigenetic markers and therapeutic targets for metastasis

Kravitz, C. J., Yan, Q., & Nguyen, D. X. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10109-y · Cited by 9

Preclinical modeling of lower-grade gliomas

Tang, L. W., Mallela, A. N., Deng, H., Richardson, T. E., Hervey‐Jumper, S. L., McBrayer, S. K., & Abdullah, K. G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1139383 · Cited by 8

Future Prospects of Therapeutic Clinical Trials in Acute Myeloid Leukemia

Khan, M., Mansoor, A., & Kadia, T. M. (2016) · Future Oncology · doi:10.2217/fon-2016-0262 · Cited by 8

An integrated genomic and metabolomic approach for defining survival time in adult oligodendrogliomas patients

Bund, C., Guergova-Kuras, M., Çiçek, A. E., Moussallieh, F., Dali‐Youcef, N., Piotto, M., Schneider, P., Heller, R., Entz‐Werlé, N., Lhermitte, B., et al. (2019) · Metabolomics · doi:10.1007/s11306-019-1522-5 · Cited by 8

IDH1 mutation inhibits differentiation of astrocytes and glioma cells with low oxoglutarate dehydrogenase expression by disturbing α-ketoglutarate-related metabolism and epigenetic modification

Zhao, Y., Yang, Y. L., Yang, R., Sun, C., Gao, X., Gu, X., Yuan, Y., Nie, Y.-T., Xu, S., Han, R., et al. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae002 · Cited by 8

Interplay between epigenetics and metabolism controls cancer stem cell plasticity

Choi, J.-E., & Baek, I. (2024) · Frontiers in Epigenetics and Epigenomics · doi:10.3389/freae.2024.1424163 · Cited by 7

An Updated Overview of the Role of CYP450 during Xenobiotic Metabolization in Regulating the Acute Myeloid Leukemia Microenvironment

Sandoval, C., Calle, Y., Godoy, K., & Farías, J. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076031 · Cited by 8

IDH1 K224 acetylation promotes colorectal cancer via miR-9-5p/NHE1 axis-mediated regulation of acidic microenvironment

Wang, B., Zhao, L., Yang, C., Lin, Y., Wang, S., Ye, Y., Luo, J., & Shen, Z. (2023) · iScience · doi:10.1016/j.isci.2023.107206 · Cited by 7

N6-Methyladenosine RNA Modification in Normal and Malignant Hematopoiesis

Weng, H., Huang, H., & Chen, J. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-7471-9_7 · Cited by 7

Integrating Full Bayesian Inference and Student's t‐Distribution Method for Enhanced Outlier Handling in Caffeine Population Pharmacokinetics: Assessing Drug–Drug Interactions with Enasidenib in Relapsed or Refractory AML and MDS Patients

Cheng, Y., Du, S., Hu, H., Wang, X., Carayannopoulos, L. N., & Li, Y. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2426 · Cited by 7

Identification of a New Selective Chemical Inhibitor of Mutant Isocitrate Dehydrogenase-1

Kim, H.-J., Choi, B. Y., & Keum, Y. (2015) · Journal of Cancer Prevention · doi:10.15430/jcp.2015.20.1.78 · Cited by 7

Structure, regulation, and function of TET family proteins

Hu, X., Chen, Y., & Zhao, Z. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-799958-6.00017-2 · Cited by 8

5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia Cells

Reilly, B. M., Luger, T., Park, S., Lio, C. J., González‐Avalos, E., Wheeler, E. C., Lee, M., Williamson, L. M., Tanaka, T. N., Diep, D. H., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0453 · Cited by 7

Metabolic control of epigenetic rearrangements in B cell pathophysiology

Calciolari, B., Scarpinello, G., Tubi, L. Q., Piazza, F., & Carrer, A. (2022) · Open Biology · doi:10.1098/rsob.220038 · Cited by 6

Distance-multiplexed sensor with metal-dielectric grating composite structure for terahertz sensing enhancement

Mao, G., Shi, T., Huang, Y., Shuncong Zhong, A., Sun, F., Zeng, Q., Zhong, Y., & Lin, T. (2024) · Optics & Laser Technology · doi:10.1016/j.optlastec.2024.112245 · Cited by 6

D-2-Hydroxyglutarate Inhibits Calcineurin Phosphatase Activity to Abolish NF-AT Activation and IL-2 Induction in Stimulated Lymphocytes

Afsari, F., & McIntyre, T. M. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200050 · Cited by 6

Regulatory variation: an emerging vantage point for cancer biology

Li, L., Lorzadeh, A., & Hirst, M. (2013) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1250 · Cited by 5

Cancer Metabolism and Its Therapeutic Implications

Logsdon, W. L. C. D., & Abbruzzese, J. L. (2013) · Journal of Cell Science & Therapy · doi:10.4172/2157-7013.1000143 · Cited by 6

Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma

van den Bent, M. J., Mellinghoff, I. K., & Bindra, R. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280967 · Cited by 6

Genetic approaches to understand cellular responses to oxygen availability

Ortmann, B. M., & Nathan, J. A. (2021) · FEBS Journal · doi:10.1111/febs.16072 · Cited by 7

Enasidenib

Krämer, A., & Bochtler, T. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91439-8_9 · Cited by 6

Emerging therapies in relapsed and refractory peripheral T-cell lymphoma.

Bachow, S. H., & O’Connor, O. A. (2015) · PubMed · Cited by 6

Metabolism and therapeutic response in acute myeloid leukemia with IDH1/2 mutations

Gabellier, L., Bosetta, E., Heiblig, M., & Sarry, J. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.01.011 · Cited by 6

Elevated 2-oxoglutarate antagonizes DNA damage responses in cholangiocarcinoma chemotherapy through regulating aspartate beta-hydroxylase

Nagaoka, K., Bai, X., Liu, D., Cao, K. Y., Mulla, J., Ji, C., Chen, H., Nisar, M. A., Bay, A., Mueller, W., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216493 · Cited by 5

Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate

Yuan, B. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51652-9_11 · Cited by 5

Myelodysplastic Syndromes

Gibson, C. J., Ebert, B. L., & Steensma, D. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00060-3 · Cited by 5

Integrative machine learning-guided in silico and in vitro approach reveals selective small molecule inhibitors targeting mutant IDH1

Bajaj, M., Kumar, R., Pandey, V., Parvez, S., Tanneru, H. K., Aparoy, P., & Karnati, R. (2025) · RSC Advances · doi:10.1039/d5ra06290j · Cited by 5

Changes in tumor and cardiac metabolism upon immune checkpoint

Leven, A., Wagner, N., Nienaber, S., Messiha, D., Tasdogan, A., & Ugurel, S. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-024-01092-8 · Cited by 7

Cancer Biology and the Principles of Targeted Cancer Drug Discovery

Hillmann, P., Schmitz, D., Mestan, J., D'Allonzo, S., & Fabbro, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12390-x · Cited by 4

mIDH-associated DNA hypermethylation in acute myeloid leukemia reflects differentiation blockage rather than inhibition of TET-mediated demethylation

Wiehle, L., Raddatz, G., Pusch, S., Gutekunst, J., von Deimling, A., Rodríguez‐Paredes, M., & Lyko, F. (2017) · Cell Stress · doi:10.15698/cst2017.10.106 · Cited by 4

Robust detection of oncometabolic aberrations by 1H–13C heteronuclear single quantum correlation in intact biological specimens

Barekatain, Y., Yan, V. C., Arthur, K., Ackroyd, J. J., Khadka, S., de Groot, J., Huse, J. T., & Müller, F. L. (2020) · Communications Biology · doi:10.1038/s42003-020-1055-5 · Cited by 4

Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation

Heiblig, M., Khalife‐Hachem, S., Willekens, C., Micol, J., Paci, A., Penard‐Lacronique, V., & de Botton, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1831909 · Cited by 4

Prognostic relevance of combined IDH1 and NPM1 mutations in the intermediate cytogenetic de novo acute myeloid leukemia

El-Lateef, A. E. A., Ismail, M. M., Almohammadi, M., & Gawaly, A. M. (2021) · Cellular and Molecular Biology · doi:10.14715/cmb/2021.67.3.12 · Cited by 4

Role of Gene Mutations in Acute Myeloid Leukemia: A Review Article

Singh, H., Kumar, M., & Kanungo, H. (2023) · Global Medical Genetics · doi:10.1055/s-0043-1770768 · Cited by 4

Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control arm

Lai, C., Leahy, T. P., Turner, A. J., Thomassen, A., Wang, L., Sheppard, A. D., & Cortes, J. E. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2514894 · Cited by 4

25 A ZEBRAFISH MODEL OF MYELODYSPLASTIC SYNDROME PRODUCED THROUGH TET2 GENOMIC EDITING

Gjini, E., Mansour, M. R., He, S., Nguyen, A., Ko, M., Sander, J. D., Joung, J. K., Zhou, Y., Zon, L. I., Rao, A. A., et al. (2015) · Leukemia Research · doi:10.1016/s0145-2126(15)30026-6 · Cited by 4

Challenging Roadblocks to Cancer Cure

Loda, M. F. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1443 · Cited by 4

Guanosine primes acute myeloid leukemia for differentiation via guanine nucleotide salvage synthesis.

Wang, H., He, X., Li, Z., Jin, H., Wang, X., & Li, L. (2022) · PubMed Central · Cited by 4

Cancer Therapies Targeting Cellular MetabolismPreprint

Morris, B. L., & Gutiérrez, A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041657 · Cited by 5

Cu‐Catalyzed Tandem Oxidation‐Intramolecular Cannizzaro Reaction of Biorenewables and Bioactive Molecules

Petkov, H., Ravutsov, M. A., Verganista, M. J., Mitrev, Y., Candeias, N. R., & Simeonov, S. P. (2024) · ChemSusChem · doi:10.1002/cssc.202400013 · Cited by 3

FLT3 and IDH1/2 Inhibitors for Acute Myeloid Leukemia: Focused Clinical Narrative Review of Forthcoming Drugs from an Indian Context

Singh, S., Jain, K., Singh, J., Garg, N., & Arora, A. (2024) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0044-1779621 · Cited by 3

GPX1 confers resistance to metabolic stress in BCR/ABL-T315I mutant chronic myeloid leukemia cells

Wang, J., Wang, J., Lin, Z.-L., Xu, N., Zhang, L., Liu, J., Gao, R., & Long, Z. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02502-z · Cited by 3

Restraining colorectal cancer with αKG

Krauß, D., & Gottlieb, E. (2020) · Nature Cancer · doi:10.1038/s43018-020-0044-4 · Cited by 3

An Integrated Immune-Related Bioinformatics Analysis in Glioma: Prognostic Signature’s Identification and Multi-Omics Mechanisms’ Exploration

Fan, X., Zhang, L., Huang, J., Zhong, Y., Fan, Y., Zhou, T., & Lu, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.889629 · Cited by 3

Metabolomic profiles as a new understanding of disease processes

Zolnikova, O. Y., Reshetova, M. S., Ivanova, M., & Ivashkin, V. T. (2022) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2022-32-1-46-52 · Cited by 4

Measurable Residual Disease Monitoring by Locked Nucleic Acid Quantitative Real-Time PCR Assay for IDH1/2 Mutation in Adult AML

Kao, H., Kuo, M., Huang, Y., Chang, H., Hu, S.-F., Huang, C., Hung, Y., Lin, T., Ou, C., Lien, M., et al. (2022) · Cancers · doi:10.3390/cancers14246205 · Cited by 3

The Noncanonical Functions of Metabolites in Tumor Progression

Wu, S., Qi, Y., & Yang, W. (2024) · Metabolites · doi:10.3390/metabo14030171 · Cited by 3

The Leukemic Isocitrate Dehydrogenase (IDH) 1/2 Mutations Impair Myeloid and Erythroid Cell Differentiation of Primary Human Hematopoietic Stem and Progenitor Cells (HSPCs)

Pierangeli, S., Donnini, S., Ciaurro, V., Milano, F., Cardinali, V., Sciabolacci, S., Cimino, G., Gionfriddo, I., Ranieri, R., Cipriani, S., et al. (2024) · Cancers · doi:10.3390/cancers16152675 · Cited by 4

Targeting Aberrant Signaling in Myeloid Malignancies

Sellar, R. S., & Losman, J.-A. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.04.001 · Cited by 3

Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation

Pasquier, F., Chahine, C., Marzac, C., & de Botton, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1792286 · Cited by 3

Une vision élargie des modèles explicatifs de la biologie des cancers

Bénard, J., & Larsen, C. (2013) · Bulletin du Cancer · doi:10.1684/bdc.2013.1752 · Cited by 3

Therapeutic Options for Aggressive T-Cell Lymphomas

Lue, J. K., Kress, A., & Amengual, J. E. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0389-7 · Cited by 3

Epigenetics: Druggable targets for anti-cancer therapies

Datta, K., & Kolaja, K. L. (2017) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2017.10.010 · Cited by 3

Enantioseparation and Detection of (R)-2-Hydroxyglutarate and (S)-2-Hydroxyglutarate by Chiral Gas Chromatography–Triple Quadrupole Mass Spectrometry

Strain, S. K., Groves, M. D., & Emmett, M. R. (2020) · Neuromethods · doi:10.1007/978-1-0716-0864-7_8 · Cited by 3

Cibler le métabolisme tumoral : efficacité et perspectives

Hadoux, J., & Massard, C. (2013) · ONCOLOGIE · doi:10.1007/s10269-013-2321-7 · Cited by 3

Imaging of Tumor Metabolism: MR Spectroscopy

Rizwan, A., & Glunde, K. (2013) · Springer eBooks · doi:10.1007/978-3-642-40412-2_8 · Cited by 3

Chromatin dynamics underlying latent responses to xenobiotics

Moggs, J. G., & Terranova, R. (2018) · Toxicology Research · doi:10.1039/c7tx00317j · Cited by 3

HIF inhibition: Current strategies and clinical challenges

Więch-Walów, A., Bartoszewska, S., Barton, A., Czechowicz, P., Dudzik, J., Wielockx, B., Collawn, J. F., & Bartoszewski, R. (2026) · Redox biology · doi:10.1016/j.redox.2026.104220 · Cited by 3

Carcinogenesis trajectories

Wang, R., & Yan, Z. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1671115 · Cited by 2

Autopalmitoylation of IDH1-R132H regulates its neomorphic activity in cancer cells

Hu, L., Lin, J., Sun, L., Berezuk, A., Tuttle, K. S., Zhu, X. Q., Seo, H., Dhe‐Paganon, S., Li, P., Sun, Y., et al. (2026) · Nature Chemical Biology · doi:10.1038/s41589-025-02131-8 · Cited by 3

R-2-Hydroxyglutarate as the Key Effector of IDH Mutations Promoting Oncogenesis

Ye, D., Ma, S., Xiong, Y., & Guan, K. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.005 · Cited by 83

IDH Mutations, 2-Oxoglutarate-dependent Dioxygenases, and Leukemia

Kaelin, W. G. (2014) · Blood · doi:10.1182/blood.v124.21.sci-6.sci-6 · Cited by 1

Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate

Chaturvedi, A., Cruz, M. M. A., Jyotsana, N., Sharma, A., Goparaju, R., Schwarzer, A., Görlich, K., Schottmann, R., Struys, E. A., Jansen, E. E. W., et al. (2016) · Leukemia · doi:10.1038/leu.2016.71 · Cited by 50

Abstract IA02: Molecular pathogenesis of IDH mutant cancers and evolving treatment strategies

Kaelin, W. G. (2015) · Cancer Research · doi:10.1158/1538-7445.brain15-ia02

Mutated IDH1 Has 2-Hydroxyglutarate-Independent Functions in Leukemogenesis

Chaturvedi, A., Cruz, M. M. A., Jyotsana, N., Sharma, A. K., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F. R., et al. (2012) · Blood · doi:10.1182/blood.v120.21.770.770